A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.

This study is comparing two procedures for treating intermediate-stage liver cancer (hepatocellular carcinoma): a standard procedure called conventional TACE (which cuts off blood supply to the tumor using particles and chemotherapy drugs), versus a newer approach called TATE (which uses a drug called tirapazamine that specifically kills cancer cells in low-oxygen environments, delivered directly through the blood vessels feeding the tumor). **You may be eligible if...** - You have been diagnosed with primary liver cancer (hepatocellular carcinoma) - Your cancer has not spread outside the liver or into blood vessels - You are eligible for the TACE or TATE liver-directed procedure - You are in reasonably good health and your liver is functioning adequately **You may NOT be eligible if...** - You have had a previous liver transplant - You have previously received radiation to the liver - You have severe heart, kidney, or other organ disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.